Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
(NASDAQ:PHVS), Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of Progression(TM)1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours) Well-tolerated safety profile of deucrictibant confirmed Efficacy and safety outcomes consistent across all HAE subtypes […]